Intermediate-size Patient Population Expanded Access Protocol

ClinicalTrials.gov ID: NCT07088159

Public ClinicalTrials.gov record NCT07088159. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Intermediate-size Patient Population Expanded Access Protocol for Tazbentetol in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this Expanded Access Program is to provide tazbentetol to ALS patients who are not eligible to enroll in an ALS clinical trial. This Expanded Access Program will assess safety and tolerability, and clinical efficacy of tazbentelol.

Study identification

NCT ID: NCT07088159
Recruitment status: Available
Study type: Expanded access
Phase: Not listed
Lead sponsor: Spinogenix; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

ALS (Amyotrophic Lateral Sclerosis)

Interventions

Tazbentetol Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Not listed
Primary completion: Not listed
Completion: Not listed
Last update posted: Jul 16, 2026

United States locations

U.S. sites: 15
U.S. states: 12
U.S. cities: 13

Facility	City	State	ZIP	Site status
University of Alabama Birmingham	Birmingham	Alabama	35233	Available
Mayo Scottsdale	Scottsdale	Arizona	85259	Available
Kaiser Permanente Los Angeles	Los Angeles	California	90027	Available
Cedar-Sinai Medical Center	Los Angeles	California	90048	Available
California Pacific Medical Center	San Francisco	California	94109	Available
Nova Southeastern University	Davie	Florida	33314	Available
Synapticure	Chicago	Illinois	60640	Available
Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire	03756	Available
Atlantic Health	Summit	New Jersey	07901	Available
New Mexico VA Health Care System	Albuquerque	New Mexico	87108	Available
NYU Langone Health	New York	New York	10017	Available
Columbia University Medical Center	New York	New York	10032	Available
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	Available
Baylor College of Medicine	Houston	Texas	77030	Available
VCU ALS Research Group	Henrico	Virginia	23233	Available

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07088159, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 16, 2026 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07088159 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →